Selected article for: "clinical development and vaccine development"

Author: Georgiou, George; Ippolito, Gregory C; Beausang, John; Busse, Christian E; Wardemann, Hedda; Quake, Stephen R
Title: The promise and challenge of high-throughput sequencing of the antibody repertoire
  • Cord-id: 8k18vl0r
  • Document date: 2014_1_19
  • ID: 8k18vl0r
    Snippet: Efforts to determine the antibody repertoire encoded by B cells in the blood or lymphoid organs using high-throughput DNA sequencing technologies have been advancing at an extremely rapid pace and are transforming our understanding of humoral immune responses. Information gained from high-throughput DNA sequencing of immunoglobulin genes (Ig-seq) can be applied to detect B-cell malignancies with high sensitivity, to discover antibodies specific for antigens of interest, to guide vaccine developm
    Document: Efforts to determine the antibody repertoire encoded by B cells in the blood or lymphoid organs using high-throughput DNA sequencing technologies have been advancing at an extremely rapid pace and are transforming our understanding of humoral immune responses. Information gained from high-throughput DNA sequencing of immunoglobulin genes (Ig-seq) can be applied to detect B-cell malignancies with high sensitivity, to discover antibodies specific for antigens of interest, to guide vaccine development and to understand autoimmunity. Rapid progress in the development of experimental protocols and informatics analysis tools is helping to reduce sequencing artifacts, to achieve more precise quantification of clonal diversity and to extract the most pertinent biological information. That said, broader application of Ig-seq, especially in clinical settings, will require the development of a standardized experimental design framework that will enable the sharing and meta-analysis of sequencing data generated by different laboratories.

    Search related documents:
    Co phrase search for related documents
    • acute sars cov respiratory syndrome coronavirus and adaptive immune system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute sars cov respiratory syndrome coronavirus and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68
    • acute sars cov respiratory syndrome coronavirus and additional approach: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and log normal: 1, 2
    • adaptive immune system and low diversity: 1
    • adaptive immune system and low frequency: 1
    • adaptive immune system and low quality: 1
    • adaptive immune system and lymphoid blood: 1
    • adaptive immunity and low concentration: 1
    • adaptive immunity and low frequency: 1, 2
    • adaptive immunity and lymph node: 1, 2, 3, 4, 5, 6, 7, 8
    • adaptive immunity and lymphocytic leukemia: 1, 2
    • adaptive immunity and lymphoid blood: 1
    • adaptive immunity and lymphoid organ: 1
    • low frequency and lymph node: 1
    • low frequency and lymphocytic leukemia: 1
    • low quality and lymph node: 1, 2, 3
    • low quality and lymphoblastic leukemia: 1
    • low quality and lymphocytic leukemia: 1